TP53 and neoplasm: Mutations in APC, KRAS, TP53, PIK3CA or PTEN and SMAD4 or SMAD2 frequently occur in these tumours, leading to dysregulation of the Wnt, MAPK, p53, PI3K and TGFβ cell signalling pathways, resulting in enhanced and sustained pro-survival and proliferation signals.